MANDIE BROWN: Open Payments
NPI 1942808506 · LACEY, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$863 in 37 payments from 18 companies in 2025. Trend: 2023 $294 · 2024 $567 · 2025 $863
Food & beverage: $863
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $159 |
| AstraZeneca Pharmaceuticals LP | 6 | $140 |
| Janssen Biotech, Inc. | 4 | $124 |
| Iovance Biotherapeutics, Inc. | 1 | $64 |
| Merck Sharp & Dohme LLC | 2 | $47 |
| Daiichi Sankyo Inc. | 2 | $45 |
| BeOne Medicines USA, Inc. | 2 | $34 |
| Blueprint Medicines Corporation | 1 | $32 |
| Genmab U.S., Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $28 |
Products named: EPKINLY, Enhertu, Amtagvi, KEYTRUDA, VENCLEXTA, DARZALEX, CALQUENCE, TEVIMBRA.
Industry payments across WA — which companies pay providers there.
